A LITERATURE REVIEW OF SGLT2 INHIBITORS IMPACT ON MAJOR NEURODEGENERATIVE DISORDERS INCLUDING ALZHEIMER AND PARKINSON DISEASE

Résumé fourni par la source

SGLT2i (sodium-glucose cotransporter 2 inhibitors), also called flozins or gliflozins, are a group of hypoglycemic agents that have revolutionized the approach in treatment of T2DM (type 2 diabetes mellitus). Recent years have witnessed a rise in number of neurological conditions, which requires novel approaches to be examined to provide neuroprotection in these patients. Some studies suggest that presence of SGLT2 receptors in the central nervous system can provide possible neuroprotective properties in Alzheimer and Parkinson disease with the use of SGLT2i. We aimed in this review to summarize current evidence of SGLT2i impact on the central nervous system (CNS), as well to define their potential role in the comprehensive management of patients with neurologic disorders. Methods and materials: A qualitative synthesis of the data focusing on SGLT2 inhibitors, Alzheimer and Parkinson disease was performed. This literature review of SGLT2 inhibitors effect on neuroprotection in neurodegenerative disorders included recent publications, primarily from the past 10 years, and was conducted from November 2023 to May 2026 using the PubMed database. We performed a systematic search using specific keywords and medical subject headings (MeSH terms) related to SGLT2 inhibitors, Alzheimer and Parkinson disease. The primary search terms were: “SGLT2 inhibitors”, “sodium-glucose cotransporter 2 inhibitors”, “Alzheimer disease”, “Parkinson disease”, “neuroprotection”, “mild cognitive impairment”, and “flozins”. The criteria for inclusion of articles were as follows: published before May 2026, written in English, peer-reviewed original research articles. Exclusion criteria included publications not available in full text, articles in languages other than English. Editorials, commentaries, and conference abstracts without full data were also excluded. Titles and abstracts of the retrieved articles were screened to determine eligibility based on the inclusion and exclusion criteria.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.